239802

Curcumin, Curcuma longa L.

A cell-permeable and irreversible antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM).

• Sinónimos: Curcumin, Curcuma longa L., 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, NOD2 Signaling Inhibitor I, Nucleotide-binding Oligomerization Domain 2 Signaling Inhibitor I, Histone Acetyltransferase Inhibitor I, HAT Inhibitor I, p300/CBP Inhibitor I
• Fórmula empírica (notación de Hill): C₂₁H₂₀O₆
• Número de CAS: 458-37-7
• Peso molecular: 368.38
• MDL number: MFCD00008365
• UNSPSC Code: 12352205
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥80% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: orange-yellow
• solubility: acetic acid: 10 mg/mL; DMSO: 5 mg/mL
• shipped in: ambient
• storage temp.: 10-30°C
• InChI: 1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13-
• InChI key: ZIUSSTSXXLLKKK-KOBPDPAPSA-N

Descripción

General description

A cell permeable antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC₅₀ = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an

IC₅₀ of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).

A cell-permeable and irreversible antitumor and anti-inflammatory agent that acts as an inhibitor of 5-lipoxygenase (IC₅₀ = 8 µM) and cyclooxygenase (IC₅₀ = 52 µM). Confers significant protection against neurotoxic and genotoxic agents. Also inhibits the induction of nitric oxide synthase in activated macrophages (IC₅₀ = 6 µM). Recently shown to inhibit the EGF receptor intrinsic kinase activity in the human epidermoid carcinoma A431 cells in a dose- and time-dependent manner. Also shown to be a p300/CREB-binding protein-specific inhibitor of histone acetyltransferase, inhibiting the acetylation of histones H3 and H4 with an IC₅₀ of ~25 µM. Does not affect p300/CREB binding protein-associated factor (PCAF).

Biochem/physiol Actions

Cell permeable: yes

Primary Target
5-lipoxygenase

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 8 µM, 52 µM, against 5-lipoxygenase, Cyclooxygenase, respectively; 6 µM inhibiting the induction of nitric oxide synthase in activated macrophages

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Hung, S., et al. 2008. Mol. Pharmacol.74, 274.
Cui, L., et al. 2007. Antimicrob. Agents Chemother.51, 488.
Salvioli, S., et al. 2007. eCAM4, 181.
Balasubramanyam, K. et al. 2004. J. Biol. Chem.279, 51163.
Brouet, I., and Okshima, H. 1995. Biochem. Biophys. Res. Commun. 206, 533.
Korutla, L., and Kumar, R. 1994. Biochim. Biophys. Acta1224, 597.
Flynn, D.L., et al. 1986. Prostagland. Leuk. Med. 22, 357.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable